Verapamil and diet halt progression of atherosclerosis in cholesterol fed rabbits.

Abstract:

:The present study was designed to evaluate the effects of oral verapamil and normal diet on regression of atherosclerotic plaque in cholesterol fed rabbits. Forty-three rabbits were separated into 6 groups and studied for 24 weeks. All groups had a cholesterol diet for the first 12 weeks. Group I was then sacrificed and had 38 +/- 23% (mean +/- standard deviation) aortic plaque. During weeks 13 to 24, group II (cholesterol diet) and group III (normal diet) had similar percentages of aortic plaque: 80 +/- 7% and 78 +/- 22%, respectively. Group IV (cholesterol diet), was treated with oral verapamil for 24 weeks and had significantly less plaque (54 +/- 10%) than group II, (80 +/- 7%). In group V (cholesterol diet), treatment with oral verapamil during weeks 13 to 24 did not significantly reduce plaque (70 +/- 23%), compared to group II, (80 +/- 7%). In group VI, normal diet and verapamil during weeks 13 to 24 significantly reduced aortic plaque (46 +/- 25) when compared to group II (80 +/- 7%). Group VI (46%) did not differ from group I (38%). It is concluded that verapamil combined with a normalized diet can halt the progression of aortic atherosclerosis after a 12 week atherogenic diet in rabbits. Verapamil or diet alone was ineffective in the second 12 weeks. Overall, verapamil was effective in preventing atherosclerosis but was ineffective in causing regression of atherosclerosis.

journal_name

Cardiovasc Drugs Ther

authors

Sievers RE,Rashid T,Garrett J,Blumlein S,Parmley WW

doi

10.1007/BF02125835

subject

Has Abstract

pub_date

1987-01-01 00:00:00

pages

65-9

issue

1

eissn

0920-3206

issn

1573-7241

journal_volume

1

pub_type

杂志文章
  • When is discontinuation of antihypertensive therapy indicated?

    abstract::Major advances have been established in the handling of hypertensive vascular disease in recent years. However, drug compliance, drug costs, and the side effects of antihypertensive agents have prompted the question of whether intermittent therapy or even possible removal of medication represents an alternative to lif...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF02026496

    authors: Schmieder RE,Rockstroh JK

    更新日期:1990-12-01 00:00:00

  • Cholesterol biosynthesis and metabolism.

    abstract::Cholesterol plays an essential role in cell membrane synthesis and in cell growth and differentiation. In mammalian cells, cholesterol can be synthesized from acetate precursors or taken up from dietary or exogenous sources. The major catabolic route for disposal of cholesterol involves conversion into excretable bile...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 社论,评审

    doi:10.1007/BF00054556

    authors: Russell DW

    更新日期:1992-04-01 00:00:00

  • Racial differences in antihypertensive therapy: evidence and implications.

    abstract::Blood pressure is controlled by many factors, and thus hypertension is a multifactorial disorder. This etiologic diversity is also reflected in the broad spectrum of different pharmacologic agents known to lower blood pressure. Most carefully controlled studies employing a single antihypertensive drug in unselected, u...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF02603180

    authors: Weinberger MH

    更新日期:1990-03-01 00:00:00

  • Mechanism of cardioprotective effect of orotic acid.

    abstract::The pyrimidine base, orotic acid (OA), markedly improves the function of recently infarcted hearts subjected to global ischemia. The mechanism of cardiac action of OA is unclear, but it has been proposed that OA acts by correcting a relative deficiency of nucleotide precursors required for RNA synthesis in the stresse...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1023/a:1007700716866

    authors: Rosenfeldt FL,Richards SM,Lin Z,Pepe S,Conyers RA

    更新日期:1998-09-01 00:00:00

  • Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists.

    abstract::Pulmonary arterial hypertension (PAH) is a group of diseases characterized by a progressive increase of pulmonary vascular resistance (PVR), initially due to abnormal pulmonary vasoconstriction in response to endothelial injury. Recent studies have here confirmed the prominent role of endothelin (ET)-1 in vasoconstric...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-015-6605-6

    authors: Madonna R,Cocco N,De Caterina R

    更新日期:2015-01-01 00:00:00

  • Pharmacogenomics to Revive Drug Development in Cardiovascular Disease.

    abstract::Investment in cardiovascular drug development is on the decline as large cardiovascular outcomes trials require considerable investments in time, efforts and financial resources. Pharmacogenomics has the potential to help revive the cardiovascular drug development pipeline by providing new and better drug targets at a...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-015-6637-y

    authors: Dubé MP,de Denus S,Tardif JC

    更新日期:2016-02-01 00:00:00

  • Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management.

    abstract::Pulmonary arterial hypertension is a rare disease, with drug-induced causes even more uncommon, accounting for only 10% of cases in large registry series. Predisposing factors for drug-induced PAH have not been completely defined. This review summarizes drugs with definite, possible, or likely association to pulmonary...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-019-06920-x

    authors: Correale M,Tricarico L,Grazioli D,Formica ES,Petrucci R,Persichella P,Di Biase M,Brunetti ND

    更新日期:2019-12-01 00:00:00

  • Effect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus.

    abstract:PURPOSE:In addition to lowering hemoglobin A1C, colesevelam has been shown to improve the atherogenic lipoprotein profile of subjects with type 2 diabetes mellitus (T2DM) when used in combination with metformin and/or sulfonylureas. A recent study evaluated the effects of colesevelam as antidiabetes monotherapy in adul...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10557-014-6516-y

    authors: Rosenson RS,Rigby SP,Jones MR,Chou HS

    更新日期:2014-06-01 00:00:00

  • Regression of left ventricular hypertrophy and improvement of renal hemodynamics in hypertensive patients treated with quinapril.

    abstract::Of 17 patients with mild to moderate essential hypertension, 8 showed echocardiographic evidence of left ventricular hypertrophy. Cardiac and renal function evaluated by glomerular filtration rate (GFR) were studied in all patients before and after 20 weeks of quinapril treatment. Systolic pressure decreased from 174....

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00877120

    authors: De Caprio L,De Rosa ML,Di Palma A,Lirato C,Caccese P,Sestito M,Lastoria S,Cicatiello AM,Rengo F

    更新日期:1994-10-01 00:00:00

  • The applied pharmacology of beta-adrenoceptor antagonists (beta blockers) in relation to clinical outcomes.

    abstract::Despite the fact that beta blockers were introduced into clinical practice 25 years ago, new beta blockers with differing kinetic and dynamic profiles continue to be developed and marketed. This overview assesses some of the more extensively studied agents from the point of view of proof of utility and the validity of...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF03029726

    authors: Fitzgerald JD

    更新日期:1991-06-01 00:00:00

  • Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril.

    abstract::The present study was performed in order to compare the efficacy, safety, and tolerability of lisinopril, a long-acting angiotensin-converting enzyme (ACE) inhibitor, with captopril, the shorter acting ACE inhibitor available, in the treatment of elderly patients (mean age 70 +/- 0.5 years) with congestive heart failu...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1023/a:1007704024393

    authors: Morisco C,Condorelli M,Crepaldi G,Rizzon P,Zardini P,Villa G,Argenziano L,Trimarco B

    更新日期:1997-03-01 00:00:00

  • Inhibition of phosphodiesterases leads to prevention of the mitochondrial permeability transition pore opening and reperfusion injury in cardiac H9c2 cells.

    abstract:PURPOSE:We tested if inhibition of phosphodiesterases (PDEs) with IBMX (1-methyl-3-isobutylxanthine) can modulate the mitochondrial permeability transition pore (mPTP) opening by inactivating glycogen synthase kinase 3β (GSK-3β). METHODS:H9c2 cells were exposed to 600 μM H(2)O(2) for 20 min to cause the mPTP opening. ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-011-6310-z

    authors: Chanoit G,Zhou J,Lee S,McIntosh R,Shen X,Zvara DA,Xu Z

    更新日期:2011-08-01 00:00:00

  • Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina.

    abstract::There is still uncertainty of whether combined therapy with a beta-blocker and calcium-channel antagonist provides additive or synergistic clinical benefits in most patients with stable angina pectoris. The comparative antianginal effect of atenolol 50 mg and atenolol 50 mg and slow release nifedipine (20 mg) twice a ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00877726

    authors: Meyer TE,Adnams C,Commerford P

    更新日期:1993-12-01 00:00:00

  • Does digoxin have a place in the treatment of the child with congenital heart disease?

    abstract::The place of digoxin in the pediatric cardiologist's armamentarium remains uncertain. As an antiarrhythmic, its use in the Wolff-Parkinson-White syndrome is obsolete, but it remains useful in the treatment of the chronic atrial fibrillation seen in some patients postoperatively and in children with dilated cardiomyopa...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF01881525

    authors: Redington AN,Carvalho JS,Shinebourne EA

    更新日期:1989-03-01 00:00:00

  • The calcium channel blocker nisoldipine delays progression of chronic renal failure in humans (preliminary communication).

    abstract::Chronic renal failure (CRF) patients with a stable course were asked to participate in a follow-up program in which they were randomized into two groups: 1) the placebo group taking their standard antihypertensive therapy without any calcium ion blocker: and 2) the nisoldipine group, those patients taking the calcium ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF02125735

    authors: Eliahou HE,Cohen D,Ben-David A,Herzog D,Serban I,Gavendo S,Kapuler S,Kogan N,Hellberg B

    更新日期:1988-01-01 00:00:00

  • A systemic combination therapy with granulocyte-colony stimulating factor plus erythropoietin aggravates the healing process of balloon-injured rat carotid arteries.

    abstract:OBJECTIVE:Percutaneous vascular interventions lead inevitably to a destruction of the endothelial lining at the site of injury. There are conflicting data on the therapeutic benefit of hematopoietic growth factors aiming at mobilisation of circulating endothelial cells to accelerate the reendothelialisation process. Ai...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-008-6117-8

    authors: Hack M,Mascha FG,Jobst BJ,Riegger GA,Griese DP

    更新日期:2008-10-01 00:00:00

  • Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina.

    abstract::Elgodipine is a new second-generation dihydropyridine calcium antagonist. Its hemodynamic and antiischemic properties were evaluated in a single-blind, placebo-controlled trial in 22 males with chronic stable angina. Coronary artery disease was angiographically confirmed. Measurements were performed with a Swan-Ganz t...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00878092

    authors: Kuhn A,Carlsson J,Miketic S,Tebbe U

    更新日期:1995-08-01 00:00:00

  • Amlodipine and physiological responses to brisk exercise in healthy subjects.

    abstract::Recent studies have questioned the safety of calcium antagonists in general, and short-acting dihydropyridine derivatives in particular. Reasons include excessive catecholamine stimulation after stress. We therefore wanted to assess whether amlodipine, a second generation dihydropyridine with a prolonged plasma half-l...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1007875603969

    authors: Stankovic S,Panz V,Klug E,Di Nicola G,Joffe BI

    更新日期:1999-11-01 00:00:00

  • Torsades de pointes: prevention and therapy.

    abstract::Torsades de pointes (TdP) is a life-threatening ventricular tachycardia that occurs in the setting of a prolonged QT interval and is most frequently related to administration of antiarrhythmic drugs. Patients with organic heart disease, with low serum electrolyte levels, with a previous episode of TdP and with bradyca...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF03029778

    authors: Keren A,Tzivoni D

    更新日期:1991-04-01 00:00:00

  • Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II).

    abstract:AIMS:We evaluated a generic quality of life (QoL) Functional Status Questionnaire (FSQ), in patients with chronic heart failure (CHF). The FSQ assesses the 3 main dimensions of QoL: physical functioning, mental health and social role. It also includes 6 single item questions about: work status, frequency of social inte...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10557-011-6284-x

    authors: Gallanagh S,Castagno D,Wilson B,Erdmann E,Zannad F,Remme WJ,Lopez-Sendon JL,Lechat P,Follath F,Höglund C,Mareev V,Sadowski Z,Seabra-Gomes RJ,Dargie HJ,McMurray JJ

    更新日期:2011-02-01 00:00:00

  • Calcium antagonists and myocardial infarction.

    abstract::In vitro and in vivo studies have demonstrated many similarities between the three calcium antagonists verapamil, nifedipine, and diltiazem in relation to protection of the myocardium during hypoxia. Important clinical differences exist between the three drugs when they are used during or after an acute myocardial inf...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF03029738

    authors: Hansen JF

    更新日期:1991-08-01 00:00:00

  • Infarct size as estimated from peak creatine kinase and lactate dehydrogenase is probably reduced in patients using calcium antagonists at the onset of symptoms.

    abstract::In animal models, calcium antagonists (Ca-A) administered before ischemia and reperfusion reduced myocardial necrosis, attenuated postischemic contractile dysfunction, and reduced tissue calcium. In 753 patients with acute myocardial infarction (AMI), we examined if use of Ca-A at the onset of symptoms (n = 127 patien...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1023/a:1007727518684

    authors: Landmark K,Abdelnoor M,Kilhovd B,Dørum HP

    更新日期:1997-09-01 00:00:00

  • Cytotoxicity of amiodarone in cultured human endothelial cells.

    abstract::As damage to the pulmonary vascular endothelium may be responsible for the lung toxicity of amiodarone, we evaluated the cytolytic toxicity of the drug in cultures of endothelial cells. Cells were cultured from human umbilical cord veins. Amiodarone caused a vacuolization of the cells with liberation of both lactate d...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00050996

    authors: Baudin B,Bénéteau-Burnat B,Giboudeau J

    更新日期:1996-11-01 00:00:00

  • Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study.

    abstract:PURPOSE:The glucose-lowering drug metformin has recently been shown to reduce myocardial oxygen consumption and increase myocardial efficiency in chronic heart failure (HF) patients without diabetes. However, it remains to be established whether these beneficial myocardial effects are associated with metformin-induced ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-07050-5

    authors: Larsen AH,Wiggers H,Dollerup OL,Jespersen NR,Hansson NH,Frøkiær J,Brøsen K,Nørrelund H,Bøtker HE,Møller N,Jessen N

    更新日期:2020-08-08 00:00:00

  • Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease.

    abstract::In both epidemiologic and genetic studies, increased levels of Lp(a) have been associated with increased risk for cardiovascular diseases as well as aortic stenosis. However, until recently, it has been difficult to lower levels of Lp(a). Diet and lifestyle have little effect on plasma levels of Lp(a) which are mainly...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-016-6654-5

    authors: Stein EA,Raal F

    更新日期:2016-02-01 00:00:00

  • Food as Medicine for Secondary Prevention of Cardiovascular Events Following an Acute Coronary Syndrome.

    abstract::Cardiovascular disease is the leading cause of death in men and women in the USA. Once a patient experiences an acute coronary syndrome (ACS), they are at increased risk for hospital readmission within 30 days and 6 months after discharge and more importantly, they have worse survival. Hospital readmissions lead to po...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-018-6798-6

    authors: Paruchuri V,Gaztanaga J,Rambhujun V,Smith R,Farkouh ME

    更新日期:2018-12-01 00:00:00

  • Cholesterol confusion in primary prevention of coronary artery disease.

    abstract::Despite the impressive relation between an increased blood cholesterol and increased mortality from coronary artery disease and despite the persuasive results of cholesterol-lowering trials in secondary prevention, there are increasing reservations about the wisdom of lowering moderately raised blood cholesterol level...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 社论

    doi:10.1007/BF00878930

    authors: Opie LH

    更新日期:1993-11-01 00:00:00

  • Porcine heparin increases postoperative bleeding in cardiopulmonary bypass patients.

    abstract::One hundred thirteen patients undergoing cardiopulmonary bypass were randomly assigned to receive either bovine or porcine heparin. Heparin was infused at 4.5 mg/kg during bypass and administered at the lesser of 70 units/kg or 5000 units/dose at 12-hour intervals postoperatively. Platelet counts decreased to 45% of p...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF01857644

    authors: Iverson LI,Duhaylongsod FG,Young JN,Ecker RR,Ennix CL Jr,Moretti RL,Farrar M,Hayes R,Lee J,May IA

    更新日期:1990-02-01 00:00:00

  • Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes.

    abstract:PURPOSE:The prevalence and consequences of prediabetic dysglycemia and undiagnosed diabetes is unknown in patients with heart failure (HF) and preserved ejection fraction (HFpEF) and has not been compared to heart failure and reduced ejection fraction (HFrEF). METHODS:We examined the prevalence and outcomes associated...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-017-6754-x

    authors: Kristensen SL,Jhund PS,Lee MMY,Køber L,Solomon SD,Granger CB,Yusuf S,Pfeffer MA,Swedberg K,McMurray JJV,CHARM Investigators and Committees.

    更新日期:2017-12-01 00:00:00

  • Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population.

    abstract:PURPOSE:A multicentre, randomized, double-blind, placebo-controlled, parallel-group study aimed to define the potential positive effect of dipeptidyl peptidase-4 inhibition on left ventricular systolic function (LVSF) beyond glycemic control in type 2 diabetes mellitus (T2DM) (DYDA 2™ trial). METHODS:Individuals with ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-019-06898-6

    authors: Giorda CB,Cioffi G,Lucci D,Nada E,Ognibeni F,Mancusi C,Latini R,Maggioni AP,DYDA 2 Investigators.

    更新日期:2019-10-01 00:00:00